These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26750558)

  • 1. CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY.
    Chambers JD; Chenoweth MD; Pyo J; Cangelosi MJ; Neumann PJ
    Int J Technol Assess Health Care; 2015 Jan; 31(5):347-54. PubMed ID: 26750558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits.
    Otero HJ; Chambers JD; Bresnahan BW; Kamae MS; Yucel KE; Neumann PJ
    Acad Radiol; 2012 Sep; 19(9):1060-5. PubMed ID: 22748382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value-based interventional pain management: a review of medicare national and local coverage determination policies.
    Manchikanti L; Falco FJ; Benyamin RM; Helm S; Singh V; Hirsch JA
    Pain Physician; 2013; 16(3):E145-80. PubMed ID: 23703416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicare's national coverage decisions for technologies, 1999-2007.
    Neumann PJ; Kamae MS; Palmer JA
    Health Aff (Millwood); 2008; 27(6):1620-31. PubMed ID: 18997221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare is scrutinizing evidence more tightly for national coverage determinations.
    Chambers JD; Chenoweth M; Cangelosi MJ; Pyo J; Cohen JT; Neumann PJ
    Health Aff (Millwood); 2015 Feb; 34(2):253-60. PubMed ID: 25646105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forcing isolation: Medicare's "in the home" coverage standard for wheelchairs.
    Medicare Rights Center
    Care Manag J; 2005; 6(1):29-37. PubMed ID: 16447855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare's national coverage decisions, 1999-2003: quality of evidence and review times.
    Neumann PJ; Divi N; Beinfeld MT; Levine BS; Keenan PS; Halpern EF; Gazelle GS
    Health Aff (Millwood); 2005; 24(1):243-54. PubMed ID: 15647237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Private payers disagree with Medicare over medical device coverage about half the time.
    Chambers JD; Chenoweth M; Thorat T; Neumann PJ
    Health Aff (Millwood); 2015 Aug; 34(8):1376-82. PubMed ID: 26240252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare program: review of national coverage determinations and local coverage determinations. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Nov; 68(216):63691-731. PubMed ID: 14610762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focus on locus: evolution of Medicare's local coverage policy.
    Foote SB
    Health Aff (Millwood); 2003; 22(4):137-46. PubMed ID: 12889761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Roadmap for Improving Medicare's Application of Coverage With Evidence Development.
    Lakdawalla D; Tunis S; Neumann P; Whicher D; Zeitler E; Liden B
    Value Health; 2024 Sep; 27(9):1191-1195. PubMed ID: 38795958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Authority of Medicare to Limit Coverage of FDA-Approved Products: Legal and Policy Considerations.
    Daval CJR; Kesselheim AS
    JAMA Intern Med; 2023 Sep; 183(9):999-1004. PubMed ID: 37505487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US hospital payment adjustments for innovative technology lag behind those in Germany, France, and Japan.
    Hernandez J; Machacz SF; Robinson JC
    Health Aff (Millwood); 2015 Feb; 34(2):261-70. PubMed ID: 25646106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions.
    Dhruva SS; Redberg RF
    Arch Intern Med; 2008 Jan; 168(2):136-40. PubMed ID: 18227358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rules for medical markets: the impact of medicare contractors on coverage policies.
    Foote SB; Wholey D; Halpern R
    Health Serv Res; 2006 Jun; 41(3 Pt 1):721-42. PubMed ID: 16704509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Medicare have an implicit cost-effectiveness threshold?
    Chambers JD; Neumann PJ; Buxton MJ
    Med Decis Making; 2010; 30(4):E14-27. PubMed ID: 20551473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated Approval.
    Neumann PJ; Crummer E; Chambers JD; Tunis SR
    Milbank Q; 2023 Dec; 101(4):1047-1075. PubMed ID: 37644739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opacity and cost effectiveness analysis in Medicare coverage decisions: health policy encounters administrative law.
    Kolber MS
    Food Drug Law J; 2009; 64(3):515-30. PubMed ID: 19999645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study.
    Roginiel AC; Dhruva SS; Ross JS
    Medicine (Baltimore); 2018 Oct; 97(40):e12715. PubMed ID: 30290675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory services regulations carry HIM implications.
    Prophet S
    J AHIMA; 2002 Sep; 73(8):20-2, 24. PubMed ID: 12233203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.